关于控股股东一致行动人部分股份被轮候冻结的公告 关于控股股东一致行动人部分股份被轮候冻结的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-086 北京中关村科技发展（控股）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，北京中关村科技发展（控股）股份有限公司（以下简称：公司）通过 中国证券登记结算有限责任公司查询，获悉： 国美电器有限公司（以下简称：国美电器）作为公司控股股东国美控股集团 有限公司的一致行动人，现持有公司 50,000,000 股流通股，持股比例为 6.64%； 国美电器所持有公司的部分股份新增被法院轮候冻结，具体情况如下： 二、股东股份累计被冻结情况 （一）截至 2025 年 8 月 7 日，上述股东及其一致行动人所持被司法冻结股 份情况如下： | 股东名称 | | | 累计被司法冻 | 累计被标记 | 占其所持股 | 占公司 | | --- | --- | --- | --- | --- | --- | --- | | | 持股数量 | 持股比例 | 结股份数量 | 股份数量 | 份比例 ...

Core Viewpoint - The company stated that the gross margin of its biopharmaceutical segment aligns with the overall level of the pharmaceutical industry, indicating a commitment to maintaining growth and technological leadership through significant R&D investments, which currently depress overall net profit levels. The company anticipates that once R&D outcomes are converted into products, this will enhance the overall net profit of the biopharmaceutical segment [1]. Group 1 - The biopharmaceutical segment's gross margin is consistent with the pharmaceutical industry's average [1] - The company is investing heavily in R&D to ensure sustained growth and technological advancement [1] - Current R&D expenditures are temporarily lowering the overall net profit levels [1] Group 2 - The company expects that successful R&D outcomes will eventually translate into products, improving net profit levels in the biopharmaceutical segment [1]

Core Points - The company held its fourth temporary meeting of the ninth board of directors for the year 2025 on August 4, 2025, where all nine directors were present and voted unanimously on several resolutions [1][3][4]. Financing Guarantees - The company approved a guarantee for Shandong Huasu to apply for a financing credit of up to 46 million yuan from Bank of Communications, with collateral provided by Shandong Zhongguancun's industrial real estate and land use rights valued at 82.163 million yuan as of June 27, 2025 [2][3]. - A guarantee was also approved for Shandong Huasu to apply for a financing credit of up to 30 million yuan from Rizhao Bank, with collateral in the form of patents [4][7]. - The company approved a guarantee for Duoduo Pharmaceutical to apply for a financing credit of up to 10 million yuan from Jiamusi Rural Credit Cooperative, with a guarantee provided by the company’s subsidiary [8]. Lease Financing - The company’s subsidiary, Beijing Huasu, plans to engage in a sale-leaseback financing lease with Jiangsu Financial Leasing, using production equipment valued at approximately 45.4187 million yuan as collateral, with a financing limit of up to 30 million yuan for a term not exceeding two years [10][11]. Joint Venture - The company plans to establish a joint venture with two other partners, contributing a total registered capital of 1 million yuan, with the company holding a 67% stake [13]. Shareholder Meeting - The company announced the convening of its fifth temporary shareholder meeting for the year 2025 [15].

关于召开 2025 年第五次临时股东会的通知 共 6 页 证券代码：000931 证券简称：中关村 公告编号：2025-085 北京中关村科技发展（控股）股份有限公司 关于召开 2025 年第五次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 公司第九届董事会 2025 年度第四次临时会议审议通过《关于召开 2025 年 第五次临时股东会的议案》。 有关法律法规、深交所业务规则和公司章程等的规定。 （1）现场会议时间：2025 年 8 月 20 日下午 14:50； （2）网络投票时间：2025 年 8 月 20 日。 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 8 月 通过深圳证券交易所互联网投票系统投票的时间为 2025 年 8 月 20 日 9:15 至 15:00 期间的任意时间。 本次股东会采用现场表决与网络投票相结合的表决方式。 （1）现场表决方式：股东本人出席现场会议或者通过授权委托书委托他人 出席现场会议进行表决。 （2）网络投票方式：公司将通过深圳证券交易所交易系统和互联网投票 ...

Group 1 - The company, Zhongguancun Science and Technology Leasing, has received approval from the Beijing Local Financial Supervision Administration for a change in senior management [1] - Ms. Yang Pengyan has been approved as the company's board secretary and financial officer, effective from August 4, 2025 [1] - Mr. Huang Wenxian's resignation will also take effect on the same date, August 4, 2025 [1]

Group 1 - The company, Zhongguancun Science and Technology Leasing (01601), has received approval from the Beijing Local Financial Supervision Administration for a change in senior management [1] - Ms. Yang Pengyan has been approved to serve as the company's board secretary and financial officer, effective from August 4, 2025 [1] - Mr. Huang Wen's resignation from his position will also take effect on August 4, 2025 [1]

格隆汇8月4日丨中关村科技租赁(01601.HK)公告，公司于近日收到北京市地方金融管理局下发的《北京 市地方金融管理局关于同意中关村科技租赁股份有限公司变更高级管理人员的批覆》(京金局发 [2025]207号)，核准杨鹏艳公司董事会秘书及财务负责人的任职资格。杨鹏艳的任职及黄闻的辞任于 2025年8月4日正式生效。 ...

Core Points - Zhongguancun announced the approval of multiple proposals during the fourth temporary meeting of the ninth board of directors for the fiscal year 2025, including a guarantee for a financing credit application of 46 million yuan by Shandong Huasu to Bank of Communications [2] Summary by Category - **Company Actions** - Zhongguancun's board approved a proposal to provide a guarantee for a financing credit application of 46 million yuan [2] - **Financial Implications** - The financing credit application is aimed at supporting Shandong Huasu's operations [2] - **Corporate Governance** - The decision was made during the fourth temporary meeting of the ninth board of directors, indicating active governance and oversight [2]

证券日报网讯 8月4日晚间，中关村（000931）发布公告称，公司将于2025年8月20日召开2025年第五次 临时股东会。本次股东会将审议《关于山东中关村为山东华素向交通银行申请4，600万元融资授信提供 担保的议案》等多项议案。 ...

Group 1 - The company Zhongguancun (SZ 000931) held its fourth temporary board meeting for the year 2025 on August 4, 2025, in Beijing, discussing the proposal for the fifth temporary shareholders' meeting [2] - For the fiscal year 2024, the company's revenue composition is as follows: Biopharmaceuticals accounted for 74.96%, Concrete for 17.48%, Elderly Health for 4.94%, and Others for 2.62% [2]